Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | GBA1 | P04062 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | CCR3 | P51677 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3597725 | 0.84 | MAPT (0.65) | MAPTGBA1SIGMAR1DRD2DRD3 | |
| SCHEMBL3601179 | 0.84 | MAPT (0.65) | MAPTGBA1SIGMAR1DRD2DRD3 | |
| SCHEMBL17048017 | 0.84 | MAPT (0.65) | MAPTGBA1SIGMAR1DRD2DRD3 | |
| SCHEMBL3601182 | 0.84 | MAPT (0.65) | MAPTGBA1SIGMAR1DRD2DRD3 | |
| SCHEMBL3597729 | 0.84 | MAPT (0.65) | MAPTGBA1SIGMAR1DRD2DRD3 | |
| SCHEMBL2271581 | 0.84 | MAPT (0.65) | MAPTGBA1SIGMAR1DRD2DRD3 | |
| SCHEMBL12424244 | 0.82 | ACHE (0.61) | MAPTGBA1ACHESIGMAR1 | |
| SCHEMBL18834714 | 0.81 | MAPT (0.60) | MAPTGBA1ACHESIGMAR1 | |
| SCHEMBL28021431 | 0.81 | GBA1 (0.50) | GBA1CCR3SIGMAR1 | |
| SCHEMBL20541127 | 0.80 | GBA1 (0.47) | MAPTGBA1ACHECCR3CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236051-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210009528-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009528-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | MAPT 2938/4885GBA1 4488/4885ACHE 2890/4885 |
| US-11236051-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | MAPT 2938/4885GBA1 4488/4885ACHE 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.